P065 characterization of early clinical and pharmacokinetic response profiles of vedolizumab: an interim analysis of enterpret, a phase 4 clinical study
Vedolizumab (VDZ), a gut-selective antibody that binds specifically to integrin α4β7, is approved for treatment of adults with moderate-to-severe ulcerative colitis (UC). An association between VDZ levels and clinical remission during induction therapy at Week (Wk) 6 was observed in pivotal trial data; the majority of nonresponders at Wk 6 had VDZ levels0.14 L/d had reduced efficacy outcomes (Osterman MT, et al. Aliment Pharmacol Ther. 2019). In the ongoing randomized controlled trial (ENTERPRET), we are evaluating whether dose escalation starting at Wk 6 in clinical nonresponders with high VDZ clearance (level
Source: Gastroenterology - Category: Gastroenterology Authors: Mark Osterman, Andres Yarur, Udayakumar Navaneethan, Alexandra James, Claudia Lopez, Maria Rosario, Karen Lasch Tags: Controlled Clinical Trials in Humans Source Type: research
More News: Clinical Trials | Gastroenterology | Inflammatory Bowel Disease | Study | Ulcerative Colitis